logo-loader

Oxford Cannabinoid Technologies: Clinical outlook for 2024

Last updated: 23:15 17 Jan 2024 AEDT, First published: 23:09 17 Jan 2024 AEDT

Oxford Cannabinoid Technologies (OCT), a UK-based therapeutics company, specialises in developing proprietary pharmaceuticals based on synthetic or sophisticated derivative cannabinoids. The focus is on clinical studies in pain relief plus, in research, on new cancer adjuvant therapies.

In autumn 2023, OCT completed dosing in its first clinical study: a single ascending dose (SAD) 32-participant safety trial on OCT461201 (“201”). The product, a synthetic molecule targetting the Cannabinoid 2 receptor, (CB2) showed no safety issues or adverse events at all doses used. This is an excellent start to the clinical stages of development.

Funding permitting, we expect the continuation of a multiple ascending dose (MAD) study in healthy participants to start around mid-2024. We understand that this will evaluate two midrange doses over 14 days. This will provide critical information on the longer-term dosing and accumulation behaviour of 201. We expect this MAD study to be completed in early autumn with data around calendar year-end 2024. It will open the way to a potential FDA IND submission which would allow US clinical studies possibly from 2025. The proposed Phase 2 indication is established chemotherapy-induced peripheral neuropathy (CIPN): nerve damage and limb pain caused by cancer chemotherapy. OCT estimates the CIPN market could be worth US$1.17 billion by 2028.

A further major market in pain control in Irritable Bowel Syndrome is being evaluated. This will require separate Phase 2 studies.

OCT has three other projects: OCT130401 (“401”) is aimed at the rapid relief of trigeminal neuralgia (sudden, severe facial nerve pain). It is a combination of two cannabinoids to be given by a metered inhaler and could enter Phase 1 in 2024. Programme 3 is a pain project derived from OCT's combined proprietary and in-licensed library of 475 molecules. Program 4 is in earlier-stage research. It aims to boost the immune response to solid tumours using cannabinoid derivatives from OCT's molecular library. An oral immuno-oncology agent could have a high commercial potential.

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points
NO INVESTMENT ADVICE

Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.

It is important for you to know that:

(a) none of the Content is, or is intended to be, general or personal advice

(b) the principal purpose of the Content is to provide factual information only and to comment on news;

(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;

(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and

(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.

The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.

In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.

FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:

This document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.

Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO

FOR OUR FULL DISCLAIMER CLICK HERE

Parbo Resources uncovers new greenstone belt at Mount Padbury

Parbo Resources (ASX:PRB) CEO Tim Campbell talked with Proactive's Stephen Gunnion about maiden reverse circulation (RC) drilling results at the Mount Padbury gold project, where drilling has confirmed greenstone beneath previously mapped granite at the GoldenEye prospect, from just 44 metres...

5 hours, 8 minutes ago